Pharvaris N.V. Business Summary

Pharvaris N.V. (PHVS) is a late-stage biopharmaceutical company focused on the development and future commercialization of novel, oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-mediated diseases. The company’s business model is currently centered on clinical-stage drug development, with revenue potential tied to the future regulatory approval and commercial launch of its lead asset, deucrictibant. Pharvaris operates through two primary therapeutic segments: on-demand treatment for acute HAE attacks (utilizing an immediate-release capsule) and long-term prophylaxis (utilizing an extended-release tablet). As of early 2026, the company is advancing pivotal Phase 3 trials (RAPIDe-3 and CHAPTER-3) and preparing global marketing authorization applications. Its primary direct competitors include Takeda (Takhzyro), BioCryst Pharmaceuticals (Orladeyo), and KalVista Pharmaceuticals (sebetralstat). Pharvaris differentiates itself by aiming to provide injectable-like efficacy with the superior convenience and tolerability of a small-molecule oral therapy, positioning it as a high-growth challenger to established injectable standards. Pharvaris was co-founded in 2015 by a team of industry veterans, including CEO Berndt Modig, who previously served as CFO of Jerini AG and Centogene N.V., and Strategic Advisor Jochen Knolle, Ph.D., a pioneer in bradykinin B2 receptor research. The current leadership team includes David Nassif (Chief Financial Officer), Peng Lu, M.D., Ph.D. (Chief Medical Officer), and Stefan Abele, Ph.D. (Chief Technical Operations Officer), many of whom bring deep pedigree from rare-disease leaders like Shire and ViroPharma. The company is backed by a robust roster of institutional investors, including General Atlantic, Forbion (formerly Life Sciences Partners), Foresite Capital, and venBio Partners. The Board of Directors is chaired by David Meeker, M.D., the former CEO of Genzyme, further reinforcing the company’s strategic focus on the rare-disease and orphan-drug markets.